sharon sanders
Editor-in-Chief & President
Re: Discussion - Dispute over ownership rights on coronavirus ncov
As Outbreak Continues, Confusion Reigns Over Virus Patents
by Kai Kupferschmidt on 28 May 2013, 4:45 PM
snip
At issue now is the MTA, a document that most biomedical laboratories routinely use when they exchange cells, samples, or pathogens. It governs, among other things, what the receiving labs can do with the virus. The MTA for the MERS virus, which was obtained by ScienceInsider, stipulates that the virus material still belongs to the original provider (in this case Erasmus MC) and that the recipient cannot give it to other labs. It also asks for written consent from Erasmus for using the virus for commercial purposes.
While Erasmus's MTA is not claiming ownership of the virus in countries where it exists or has been isolated, it is protecting its legal ownership of the virus samples that it shares with other institutions, says David Fidler, a legal scholar at the Indiana University, Bloomington, who has studied the international sharing of pathogens. "The press release and the MTA preserve Erasmus's rights to seek IP rights for vaccines and medicines related to research done on the virus sample from Saudi Arabia," he says. But Erasmus's MTA is "a fairly standard agreement," Fidler says. "There is nothing here that suggests to me that this needed a massive amount of negotiation ? nothing where I thought that's unusual or highly restrictive."
more...
http://news.sciencemag.org/scienceinsider/2013/05/as-outbreak-continues-confusion-.html
As Outbreak Continues, Confusion Reigns Over Virus Patents
by Kai Kupferschmidt on 28 May 2013, 4:45 PM
snip
At issue now is the MTA, a document that most biomedical laboratories routinely use when they exchange cells, samples, or pathogens. It governs, among other things, what the receiving labs can do with the virus. The MTA for the MERS virus, which was obtained by ScienceInsider, stipulates that the virus material still belongs to the original provider (in this case Erasmus MC) and that the recipient cannot give it to other labs. It also asks for written consent from Erasmus for using the virus for commercial purposes.
While Erasmus's MTA is not claiming ownership of the virus in countries where it exists or has been isolated, it is protecting its legal ownership of the virus samples that it shares with other institutions, says David Fidler, a legal scholar at the Indiana University, Bloomington, who has studied the international sharing of pathogens. "The press release and the MTA preserve Erasmus's rights to seek IP rights for vaccines and medicines related to research done on the virus sample from Saudi Arabia," he says. But Erasmus's MTA is "a fairly standard agreement," Fidler says. "There is nothing here that suggests to me that this needed a massive amount of negotiation ? nothing where I thought that's unusual or highly restrictive."
more...
http://news.sciencemag.org/scienceinsider/2013/05/as-outbreak-continues-confusion-.html